<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950856</url>
  </required_header>
  <id_info>
    <org_study_id>V114-020</org_study_id>
    <secondary_id>V114-020</secondary_id>
    <secondary_id>2018-004266-33</secondary_id>
    <nct_id>NCT03950856</nct_id>
  </id_info>
  <brief_title>Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)</brief_title>
  <acronym>PNEU-TRUE</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives are to evaluate the safety and tolerability of V114 and to compare the&#xD;
      serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3&#xD;
      different lots of V114. The primary hypothesis is that all 3 lots of V114 are equivalent as&#xD;
      measured by the serotype-specific OPA GMTs for 15 serotypes in V114 at 30 days&#xD;
      postvaccination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Actual">April 3, 2020</completion_date>
  <primary_completion_date type="Actual">April 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of redness/erythema, swelling, and tenderness/pain. The 95% confidence interval (CI) were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with solicited injection-site AEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of redness/erythema, swelling, and tenderness/pain. Per the statistical analysis plan, within-group CIs were not calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consisted of muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The 95% CI were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with solicited systemic AEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consisted of muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Per the statistical analysis plan, within-group CIs were not calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Vaccine-related Serious Adverse Event Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. Relatedness of an SAE to the study vaccine is determined by the investigator. The 95% CI were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with SAEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Vaccine-related Serious Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. Relatedness of an SAE to the study vaccine is determined by the investigator. Per the statistical analysis plan, within-group CIs were not calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA) Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Day 30</time_frame>
    <description>Opsonization of pneumococci for phagocytosis is an important mechanism by which antibodies to polysaccharides protect against disease in vivo. Sera from participants was used to measure geometric mean titer (GMT) of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, using the Multiplexed Opsonophagocytic Assay (MOPA). Per the statistical analysis plan, within-group CIs were not calculated. 95% CIs were calculated for the GMT ratios between pairs of V114 lots by a constrained longitudinal data analysis (cLDA) model; and the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Immunoglobulin G (IgG) Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Day 30</time_frame>
    <description>The geometric mean concentration (GMC) of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by multiplex electrochemiluminescence (ECL) using the pneumococcal electrochemiluminescence (PnECL) v2.0 assay. Per the statistical analysis plan, within-group CIs were not calculated; and the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific IgG Following Vaccination: Combined Lots of V114 or Prevnar 13™</measure>
    <time_frame>Day 30</time_frame>
    <description>The GMC of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. Per the statistical analysis plan, within-group CIs were not calculated,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in Serotype-specific OPA Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Sera from participants was used to measure GMT of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, using the MOPA which reads the reciprocal of the highest dilution that gives ≥50% bacterial killing. The Geometric Mean Fold Rise (GMFR) is the geometric mean of the ratio Day 30/Day 1 OPA responses. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>The geometric mean concentration (GMC) of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. The GMFR is the geometric mean of the ratio Day 30/Day 1 IgG concentration. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥4 Fold Change in Serotype-specific OPA Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Sera from participants was used to measure GMT of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, with the MOPA which reads the reciprocal of the highest dilution (1/dil) that gives ≥50% bacterial killing. Percentage of participants with a ≥ 4-fold change from Day 1 (baseline) to Day 30 (Day 30/Day 1) are presented. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥4 Fold Change in Serotype-specific IgG Following Vaccination With Separate V114 Lots</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>The geometric mean concentration of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. Percentage of participants with a ≥ 4-fold change from Day 1 (baseline) to Day 30 (Day 30/ Day 1) are presented. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2340</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>Pneumonia, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>V114 Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V114 Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V114 Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.</description>
    <arm_group_label>V114 Lot 1</arm_group_label>
    <arm_group_label>V114 Lot 2</arm_group_label>
    <arm_group_label>V114 Lot 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has good health in the opinion of the investigator. Any underlying chronic&#xD;
             condition must be documented to be in stable condition according to the investigator's&#xD;
             judgment.&#xD;
&#xD;
          -  Contraceptive use by women should be consistent with local regulations regarding the&#xD;
             methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and is not a woman of childbearing potential (WOCBP) OR a WOCBP who&#xD;
             agrees to use agreed upon contraception during the treatment period and for at least 6&#xD;
             weeks after the last dose of study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of invasive pneumococcal disease (IPD) (positive blood culture, positive&#xD;
             cerebrospinal fluid culture, or positive culture at another sterile site) or known&#xD;
             history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day&#xD;
             1).&#xD;
&#xD;
          -  Known hypersensitivity to any component of pneumococcal polysaccharide vaccine,&#xD;
             pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid-containing vaccine.&#xD;
&#xD;
          -  Known or suspected impairment of immunological function including, but not limited to,&#xD;
             a history of congenital or acquired immunodeficiency, documented human&#xD;
             immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of&#xD;
             autoimmune disease.&#xD;
&#xD;
          -  Coagulation disorder contraindicating intramuscular vaccinations.&#xD;
&#xD;
          -  Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or&#xD;
             axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for&#xD;
             any acute illness occurring within 72 hours before receipt of study vaccine.&#xD;
&#xD;
          -  History of malignancy ≤5 years prior to signing informed consent, except for&#xD;
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.&#xD;
&#xD;
          -  A WOCBP who has a positive urine or serum pregnancy test before the first vaccination&#xD;
             at Visit 1 (Day 1).&#xD;
&#xD;
          -  Has received any pneumococcal vaccine or is expected to receive any pneumococcal&#xD;
             vaccine during the study outside of the protocol.&#xD;
&#xD;
          -  Has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14&#xD;
             consecutive days and has not completed intervention at least 30 days before study&#xD;
             entry.&#xD;
&#xD;
          -  Has received systemic corticosteroids exceeding physiologic replacement doses&#xD;
             (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination.&#xD;
             (Note: Topical, ophthalmic, intra-articular or soft-tissue [e.g., bursa, tendon&#xD;
             steroid injections], and inhaled/nebulized steroids are permitted).&#xD;
&#xD;
          -  Is receiving immunosuppressive therapy, including chemotherapeutic agents used to&#xD;
             treat cancer or other conditions, and interventions associated with organ or bone&#xD;
             marrow transplantation, or autoimmune disease.&#xD;
&#xD;
          -  Has received any non-live vaccine within the 14 days before receipt of any study&#xD;
             vaccine or is scheduled to receive any non-live vaccine within 30 days following&#xD;
             receipt of any study vaccine. (Exception: Inactivated influenza vaccine may be&#xD;
             administered but must be given at least 7 days before receipt of any study vaccine or&#xD;
             at least 15 days after receipt of any study vaccine.)&#xD;
&#xD;
          -  Has received any live vaccine within 30 days before receipt of any study vaccine or is&#xD;
             scheduled to receive any live vaccine within 30 days following receipt of any study&#xD;
             vaccine. If this exclusion criterion is met, then Day 1 Visit may be rescheduled for a&#xD;
             time when criterion is not met.&#xD;
&#xD;
          -  Has received a blood transfusion or blood products, including immunoglobulin, within&#xD;
             the 6 months before receipt of study vaccine or is scheduled to receive a blood&#xD;
             transfusion or blood product within 30 days of receipt of study vaccine. Autologous&#xD;
             blood transfusions are not considered an exclusion criterion.&#xD;
&#xD;
          -  Currently participating in or has participated in an interventional clinical study&#xD;
             with an investigational compound or device within 2 months of participating in this&#xD;
             current study.&#xD;
&#xD;
          -  In the opinion of the investigator, has a history of clinically relevant drug or&#xD;
             alcohol use that would interfere with participation in protocol-specified activities.&#xD;
&#xD;
          -  History or current evidence of any condition, therapy, laboratory abnormality, or&#xD;
             other circumstance that might expose the participant to risk by participating in the&#xD;
             study, confound the results of the study, or interfere with the participant's&#xD;
             participation for the full duration of the study.&#xD;
&#xD;
          -  Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or&#xD;
             child) who is investigational site or Sponsor staff directly involved with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. ( Site 1031)</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus ( Site 1043)</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southland Clinical Research Center ( Site 1027)</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Trials Inc. ( Site 1003)</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC ( Site 1019)</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Foundation ( Site 1006)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research ( Site 1041)</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta California Medical Group ( Site 1020)</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC ( Site 1029)</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites-DeLand Clinical Research Unit ( Site 1026)</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research ( Site 1014)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L&amp;C Professional Medical Research Institute ( Site 1012)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Science Research ( Site 1015)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS Miami Research Associates ( Site 1035)</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research ( Site 1040)</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group ( Site 1010)</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Network (Marlboro, MA) ( Site 1025)</name>
      <address>
        <city>Marlborough</city>
        <state>Massachusetts</state>
        <zip>01752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Clinical Research Center of Nevada, LLC ( Site 1044)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest CARE Center ( Site 1011)</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corning Center For Clinical Research ( Site 1033)</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc. ( Site 1024)</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc. ( Site 1039)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston Salem ( Site 1037)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unity Clinical Research ( Site 1036)</name>
      <address>
        <city>Lindsay</city>
        <state>Oklahoma</state>
        <zip>73052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center ( Site 1034)</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellness Clinical Research Associates ( Site 1038)</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group ( Site 1042)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus ( Site 1000)</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research ( Site 1028)</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists ( Site 1013)</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Pty Ltd - Blacktown Clinic ( Site 6006)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Network ( Site 6000)</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital ( Site 6001)</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trialswest ( Site 6004)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Alemana de Santiago Adolescencia ( Site 2000)</name>
      <address>
        <city>Santiago</city>
        <state>Región Metropolitana</state>
        <zip>7650568</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESFAM Colina ( Site 2002)</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>9350079</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional del Torax ( Site 2004)</name>
      <address>
        <city>Santiago</city>
        <zip>7500691</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica UC CICUC ( Site 2001)</name>
      <address>
        <city>Santiago</city>
        <zip>8330034</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 2003)</name>
      <address>
        <city>Temuco</city>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital ( Site 3003)</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitets hospital ( Site 3004)</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR. Center for Clinical and Basic Research ( Site 3000)</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 3005)</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital ( Site 3002)</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 3001)</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Etela-Helsingin Rokotetutkimusklinikka ( Site 4006)</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarvenpaan rokotetutkimuskeskus ( Site 4005)</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkolan rokotetutkimusklinikka ( Site 4002)</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Oulun rokotetutkimusklinikka ( Site 4001)</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Porin rokotetutkimusklinikka ( Site 4004)</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto - Tampereen rokotetutkimusklinikka ( Site 4000)</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turun rokotetutkimuskeskus ( Site 4003)</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova Lakeside Dedicated Research Centre ( Site 5004)</name>
      <address>
        <city>Corby</city>
        <state>Northamptonshire</state>
        <zip>NN17 2UR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP Direct ( Site 5000)</name>
      <address>
        <city>Harrow</city>
        <zip>HA2 0RQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vauxhall Primary Health Care ( Site 5002)</name>
      <address>
        <city>Liverpool</city>
        <zip>L5 8XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <results_first_submitted>March 16, 2021</results_first_submitted>
  <results_first_submitted_qc>March 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2021</results_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03950856/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy males or females ≥50 years of age without a history of invasive pneumococcal disease or prior administration of any pneumococcal vaccine were enrolled in this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>V114 Lot 1</title>
          <description>Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="P2">
          <title>V114 Lot 2</title>
          <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="P3">
          <title>V114 Lot 3</title>
          <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="P4">
          <title>Prevnar13™</title>
          <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="702"/>
                <participants group_id="P2" count="704"/>
                <participants group_id="P3" count="701"/>
                <participants group_id="P4" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="698"/>
                <participants group_id="P2" count="704"/>
                <participants group_id="P3" count="700"/>
                <participants group_id="P4" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="683"/>
                <participants group_id="P2" count="689"/>
                <participants group_id="P3" count="683"/>
                <participants group_id="P4" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to phone</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V114 Lot 1</title>
          <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="B2">
          <title>V114 Lot 2</title>
          <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="B3">
          <title>V114 Lot 3</title>
          <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="B4">
          <title>Prevnar13™</title>
          <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="702"/>
            <count group_id="B2" value="704"/>
            <count group_id="B3" value="701"/>
            <count group_id="B4" value="233"/>
            <count group_id="B5" value="2340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="7.5"/>
                    <measurement group_id="B2" value="64.4" spread="7.8"/>
                    <measurement group_id="B3" value="64.3" spread="7.4"/>
                    <measurement group_id="B4" value="64.2" spread="8.0"/>
                    <measurement group_id="B5" value="64.4" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="387"/>
                    <measurement group_id="B2" value="422"/>
                    <measurement group_id="B3" value="404"/>
                    <measurement group_id="B4" value="133"/>
                    <measurement group_id="B5" value="1346"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="297"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="464"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="560"/>
                    <measurement group_id="B2" value="540"/>
                    <measurement group_id="B3" value="558"/>
                    <measurement group_id="B4" value="190"/>
                    <measurement group_id="B5" value="1848"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="644"/>
                    <measurement group_id="B2" value="621"/>
                    <measurement group_id="B3" value="628"/>
                    <measurement group_id="B4" value="203"/>
                    <measurement group_id="B5" value="2096"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination With Separate V114 Lots</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of redness/erythema, swelling, and tenderness/pain. The 95% confidence interval (CI) were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with solicited injection-site AEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
        <time_frame>Up to Day 5</time_frame>
        <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination With Separate V114 Lots</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of redness/erythema, swelling, and tenderness/pain. The 95% confidence interval (CI) were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with solicited injection-site AEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
          <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="699"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="8.0" upper_limit="12.6"/>
                    <measurement group_id="O2" value="11.5" lower_limit="9.2" upper_limit="14.1"/>
                    <measurement group_id="O3" value="11.0" lower_limit="8.8" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" lower_limit="62.5" upper_limit="69.6"/>
                    <measurement group_id="O2" value="67.0" lower_limit="63.4" upper_limit="70.5"/>
                    <measurement group_id="O3" value="67.3" lower_limit="63.7" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="13.0" upper_limit="18.5"/>
                    <measurement group_id="O2" value="15.8" lower_limit="13.2" upper_limit="18.7"/>
                    <measurement group_id="O3" value="14.7" lower_limit="12.2" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of redness/erythema, swelling, and tenderness/pain. Per the statistical analysis plan, within-group CIs were not calculated.</description>
        <time_frame>Up to Day 5</time_frame>
        <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Combined Lots 1,2 and 3</title>
            <description>Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Solicited Injection-site Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of redness/erythema, swelling, and tenderness/pain. Per the statistical analysis plan, within-group CIs were not calculated.</description>
          <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2103"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8"/>
                    <measurement group_id="O2" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection site erythema: V114 Combined Lots - Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.538</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
            <estimate_desc>V114 Combined Lots minus Prevnar 13™</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection site pain: V114 Combined Lots - Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>14.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.9</ci_lower_limit>
            <ci_upper_limit>21.4</ci_upper_limit>
            <estimate_desc>V114 Combined Lots minus Prevnar 13™</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection site swelling: V114 Combined Lots - Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.686</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
            <estimate_desc>V114 Combined Lots minus Prevnar 13™</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination With Separate V114 Lots</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consisted of muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The 95% CI were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with solicited systemic AEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
        <time_frame>Up to Day 14</time_frame>
        <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination With Separate V114 Lots</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consisted of muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The 95% CI were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with solicited systemic AEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
          <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="699"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="5.7" upper_limit="9.8"/>
                    <measurement group_id="O2" value="7.0" lower_limit="5.2" upper_limit="9.1"/>
                    <measurement group_id="O3" value="8.4" lower_limit="6.5" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="19.0" upper_limit="25.3"/>
                    <measurement group_id="O2" value="20.9" lower_limit="17.9" upper_limit="24.1"/>
                    <measurement group_id="O3" value="21.6" lower_limit="18.6" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="15.4" upper_limit="21.2"/>
                    <measurement group_id="O2" value="19.9" lower_limit="17.0" upper_limit="23.0"/>
                    <measurement group_id="O3" value="18.6" lower_limit="15.8" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="24.7" upper_limit="31.5"/>
                    <measurement group_id="O2" value="24.3" lower_limit="21.2" upper_limit="27.6"/>
                    <measurement group_id="O3" value="28.4" lower_limit="25.1" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consisted of muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Per the statistical analysis plan, within-group CIs were not calculated.</description>
        <time_frame>Up to Day 14</time_frame>
        <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Combined Lots 1,2 and 3</title>
            <description>Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consisted of muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. Per the statistical analysis plan, within-group CIs were not calculated.</description>
          <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2103"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9"/>
                    <measurement group_id="O2" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arthralgia: V114 Combined Lots - Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.272</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
            <estimate_desc>V114 Combined Lots minus Prevnar 13™</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fatigue: V114 Combined Lots - Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.812</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>V114 Combined Lots minus Prevnar 13™</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Headache: V114 Combined Lots - Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.947</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
            <estimate_desc>V114 Combined Lots minus Prevnar 13™</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Myalgia: V114 Combined Lots - Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
            <estimate_desc>V114 Combined Lots minus Prevnar 13™</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Vaccine-related Serious Adverse Event Following Vaccination With Separate V114 Lots</title>
        <description>A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. Relatedness of an SAE to the study vaccine is determined by the investigator. The 95% CI were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with SAEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
        <time_frame>Up to Month 6</time_frame>
        <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Vaccine-related Serious Adverse Event Following Vaccination With Separate V114 Lots</title>
          <description>A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. Relatedness of an SAE to the study vaccine is determined by the investigator. The 95% CI were based on the exact binomial method proposed by Clopper and Pearson. Following vaccination with the three lots of V114 the percentage of participants with SAEs was assessed. Per the statistical analysis plan, the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
          <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="699"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Vaccine-related Serious Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</title>
        <description>A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. Relatedness of an SAE to the study vaccine is determined by the investigator. Per the statistical analysis plan, within-group CIs were not calculated.</description>
        <time_frame>Up to Month 6</time_frame>
        <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Combined Lots 1,2 and 3</title>
            <description>Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Vaccine-related Serious Adverse Event Following Vaccination: Combined Lots of V114 or Prevnar 13™</title>
          <description>A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. Relatedness of an SAE to the study vaccine is determined by the investigator. Per the statistical analysis plan, within-group CIs were not calculated.</description>
          <population>Randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2103"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>V114 Combined Lots - Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Miettinen &amp; Nurminen</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>V114 Combined Lots minus Prevnar 13™</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA) Following Vaccination With Separate V114 Lots</title>
        <description>Opsonization of pneumococci for phagocytosis is an important mechanism by which antibodies to polysaccharides protect against disease in vivo. Sera from participants was used to measure geometric mean titer (GMT) of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, using the Multiplexed Opsonophagocytic Assay (MOPA). Per the statistical analysis plan, within-group CIs were not calculated. 95% CIs were calculated for the GMT ratios between pairs of V114 lots by a constrained longitudinal data analysis (cLDA) model; and the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
        <time_frame>Day 30</time_frame>
        <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA) Following Vaccination With Separate V114 Lots</title>
          <description>Opsonization of pneumococci for phagocytosis is an important mechanism by which antibodies to polysaccharides protect against disease in vivo. Sera from participants was used to measure geometric mean titer (GMT) of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, using the Multiplexed Opsonophagocytic Assay (MOPA). Per the statistical analysis plan, within-group CIs were not calculated. 95% CIs were calculated for the GMT ratios between pairs of V114 lots by a constrained longitudinal data analysis (cLDA) model; and the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
          <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
          <units>1/dil</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="698"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.5"/>
                    <measurement group_id="O2" value="251.6"/>
                    <measurement group_id="O3" value="239.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.3"/>
                    <measurement group_id="O2" value="232.2"/>
                    <measurement group_id="O3" value="214.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1073.1"/>
                    <measurement group_id="O2" value="1303.7"/>
                    <measurement group_id="O3" value="1074.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389.8"/>
                    <measurement group_id="O2" value="461.6"/>
                    <measurement group_id="O3" value="391.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="686"/>
                    <count group_id="O2" value="691"/>
                    <count group_id="O3" value="686"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5845.0"/>
                    <measurement group_id="O2" value="6077.6"/>
                    <measurement group_id="O3" value="6123.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5160.6"/>
                    <measurement group_id="O2" value="5362.7"/>
                    <measurement group_id="O3" value="5109.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="692"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="687"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3757.7"/>
                    <measurement group_id="O2" value="4590.5"/>
                    <measurement group_id="O3" value="4202.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="691"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1708.4"/>
                    <measurement group_id="O2" value="1690.6"/>
                    <measurement group_id="O3" value="1749.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="687"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2364.8"/>
                    <measurement group_id="O2" value="2509.6"/>
                    <measurement group_id="O3" value="2050.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3880.8"/>
                    <measurement group_id="O2" value="3522.4"/>
                    <measurement group_id="O3" value="3381.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3384.7"/>
                    <measurement group_id="O2" value="3774.8"/>
                    <measurement group_id="O3" value="3498.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1866.4"/>
                    <measurement group_id="O2" value="2017.8"/>
                    <measurement group_id="O3" value="1993.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="690"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="686"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2222.9"/>
                    <measurement group_id="O2" value="2417.8"/>
                    <measurement group_id="O3" value="2133.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="688"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="684"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2617.4"/>
                    <measurement group_id="O2" value="2761.6"/>
                    <measurement group_id="O3" value="2676.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="691"/>
                    <count group_id="O2" value="690"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7758.1"/>
                    <measurement group_id="O2" value="7736.9"/>
                    <measurement group_id="O3" value="7365.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 22F: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 22F: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 22F: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 33F: GMT Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 33F: GMT Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 33F: GMT Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lower and upper p-values ≤ 0.025 support a conclusion of equivalence.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Identical p-values for the lower and upper bounds.</p_value_desc>
            <method>cLDA model</method>
            <method_desc>P-value for the comparison of the GMT ratio to the lower bound (0.5). P-value for the comparison of the GMT ratio to the upper bound (2.0).</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMT ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Serotype-specific Immunoglobulin G (IgG) Following Vaccination With Separate V114 Lots</title>
        <description>The geometric mean concentration (GMC) of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by multiplex electrochemiluminescence (ECL) using the pneumococcal electrochemiluminescence (PnECL) v2.0 assay. Per the statistical analysis plan, within-group CIs were not calculated; and the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
        <time_frame>Day 30</time_frame>
        <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Serotype-specific Immunoglobulin G (IgG) Following Vaccination With Separate V114 Lots</title>
          <description>The geometric mean concentration (GMC) of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by multiplex electrochemiluminescence (ECL) using the pneumococcal electrochemiluminescence (PnECL) v2.0 assay. Per the statistical analysis plan, within-group CIs were not calculated; and the Prevnar 13™ treatment group was not included as it was not analyzed with the same approach as the separate V114 lots.</description>
          <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
          <units>μg/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="698"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91"/>
                    <measurement group_id="O2" value="4.05"/>
                    <measurement group_id="O3" value="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74"/>
                    <measurement group_id="O2" value="0.86"/>
                    <measurement group_id="O3" value="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="692"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79"/>
                    <measurement group_id="O2" value="2.18"/>
                    <measurement group_id="O3" value="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.81"/>
                    <measurement group_id="O2" value="4.63"/>
                    <measurement group_id="O3" value="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.09"/>
                    <measurement group_id="O2" value="8.84"/>
                    <measurement group_id="O3" value="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.92"/>
                    <measurement group_id="O2" value="11.46"/>
                    <measurement group_id="O3" value="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71"/>
                    <measurement group_id="O2" value="7.11"/>
                    <measurement group_id="O3" value="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20"/>
                    <measurement group_id="O2" value="4.44"/>
                    <measurement group_id="O3" value="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.82"/>
                    <measurement group_id="O2" value="11.38"/>
                    <measurement group_id="O3" value="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.07"/>
                    <measurement group_id="O2" value="11.81"/>
                    <measurement group_id="O3" value="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.45"/>
                    <measurement group_id="O2" value="17.34"/>
                    <measurement group_id="O3" value="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.78"/>
                    <measurement group_id="O2" value="11.22"/>
                    <measurement group_id="O3" value="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.38"/>
                    <measurement group_id="O2" value="7.97"/>
                    <measurement group_id="O3" value="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12"/>
                    <measurement group_id="O2" value="4.41"/>
                    <measurement group_id="O3" value="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="693"/>
                    <count group_id="O2" value="693"/>
                    <count group_id="O3" value="688"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92"/>
                    <measurement group_id="O2" value="10.88"/>
                    <measurement group_id="O3" value="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 22F: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 22F: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 22F: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 33F: GMC Ratio V114 Lot 1 / V114 Lot 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 2</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 33F: GMC Ratio V114 Lot 1 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Lot 1 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Serotype 33F: GMC Ratio V114 Lot 2 / V114 Lot 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Lot 2 divided by Lot 3</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Serotype-specific IgG Following Vaccination: Combined Lots of V114 or Prevnar 13™</title>
        <description>The GMC of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. Per the statistical analysis plan, within-group CIs were not calculated,</description>
        <time_frame>Day 30</time_frame>
        <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Combined Lots 1,2 and 3</title>
            <description>Single IM dose at 0.5 mL of either V114 Lots 1,2 or 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Serotype-specific IgG Following Vaccination: Combined Lots of V114 or Prevnar 13™</title>
          <description>The GMC of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. Per the statistical analysis plan, within-group CIs were not calculated,</description>
          <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
          <units>μg/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2102"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91"/>
                    <measurement group_id="O2" value="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77"/>
                    <measurement group_id="O2" value="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2073"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87"/>
                    <measurement group_id="O2" value="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14"/>
                    <measurement group_id="O2" value="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.38"/>
                    <measurement group_id="O2" value="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.92"/>
                    <measurement group_id="O2" value="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19"/>
                    <measurement group_id="O2" value="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30"/>
                    <measurement group_id="O2" value="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89"/>
                    <measurement group_id="O2" value="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.08"/>
                    <measurement group_id="O2" value="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.18"/>
                    <measurement group_id="O2" value="16.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.52"/>
                    <measurement group_id="O2" value="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58"/>
                    <measurement group_id="O2" value="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10"/>
                    <measurement group_id="O2" value="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2074"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.03"/>
                    <measurement group_id="O2" value="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 22F: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>12.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.11</ci_lower_limit>
            <ci_upper_limit>14.74</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 33F: GMC Ratio V114 Combined Lots / Prevnar 13™</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMC Ratio</param_type>
            <param_value>9.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.96</ci_lower_limit>
            <ci_upper_limit>11.13</ci_upper_limit>
            <estimate_desc>V114 Combined Lots divided by Prevnar 13™</estimate_desc>
            <other_analysis_desc>GMC ratio and 95% CI were estimated from a cLDA model.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) in Serotype-specific OPA Following Vaccination With Separate V114 Lots</title>
        <description>Sera from participants was used to measure GMT of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, using the MOPA which reads the reciprocal of the highest dilution that gives ≥50% bacterial killing. The Geometric Mean Fold Rise (GMFR) is the geometric mean of the ratio Day 30/Day 1 OPA responses. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
        <time_frame>Day 1 (Baseline) and Day 30</time_frame>
        <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) in Serotype-specific OPA Following Vaccination With Separate V114 Lots</title>
          <description>Sera from participants was used to measure GMT of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, using the MOPA which reads the reciprocal of the highest dilution that gives ≥50% bacterial killing. The Geometric Mean Fold Rise (GMFR) is the geometric mean of the ratio Day 30/Day 1 OPA responses. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
          <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="698"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="667"/>
                    <count group_id="O3" value="661"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="13.9" upper_limit="18.2"/>
                    <measurement group_id="O2" value="16.5" lower_limit="14.6" upper_limit="18.8"/>
                    <measurement group_id="O3" value="15.4" lower_limit="13.6" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="666"/>
                    <count group_id="O2" value="665"/>
                    <count group_id="O3" value="657"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5.9" upper_limit="7.2"/>
                    <measurement group_id="O2" value="7.6" lower_limit="6.8" upper_limit="8.4"/>
                    <measurement group_id="O3" value="6.9" lower_limit="6.2" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="670"/>
                    <count group_id="O2" value="663"/>
                    <count group_id="O3" value="658"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="15.4" upper_limit="19.8"/>
                    <measurement group_id="O2" value="20.7" lower_limit="18.3" upper_limit="23.4"/>
                    <measurement group_id="O3" value="16.5" lower_limit="14.6" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="675"/>
                    <count group_id="O3" value="665"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="9.9" upper_limit="12.8"/>
                    <measurement group_id="O2" value="13.3" lower_limit="11.8" upper_limit="15.1"/>
                    <measurement group_id="O3" value="11.1" lower_limit="9.8" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="620"/>
                    <count group_id="O2" value="618"/>
                    <count group_id="O3" value="611"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="12.1" upper_limit="15.5"/>
                    <measurement group_id="O2" value="14.1" lower_limit="12.5" upper_limit="16.0"/>
                    <measurement group_id="O3" value="14.6" lower_limit="12.8" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="659"/>
                    <count group_id="O2" value="658"/>
                    <count group_id="O3" value="653"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" lower_limit="29.0" upper_limit="38.5"/>
                    <measurement group_id="O2" value="31.2" lower_limit="27.0" upper_limit="36.1"/>
                    <measurement group_id="O3" value="34.9" lower_limit="30.2" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="648"/>
                    <count group_id="O2" value="638"/>
                    <count group_id="O3" value="646"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="10.4" upper_limit="13.7"/>
                    <measurement group_id="O2" value="14.3" lower_limit="12.4" upper_limit="16.5"/>
                    <measurement group_id="O3" value="12.9" lower_limit="11.3" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="652"/>
                    <count group_id="O2" value="650"/>
                    <count group_id="O3" value="641"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.4" upper_limit="5.3"/>
                    <measurement group_id="O2" value="4.8" lower_limit="4.3" upper_limit="5.3"/>
                    <measurement group_id="O3" value="5.0" lower_limit="4.5" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="671"/>
                    <count group_id="O2" value="667"/>
                    <count group_id="O3" value="662"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="6.6" upper_limit="8.6"/>
                    <measurement group_id="O2" value="7.6" lower_limit="6.7" upper_limit="8.7"/>
                    <measurement group_id="O3" value="6.2" lower_limit="5.4" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="669"/>
                    <count group_id="O2" value="662"/>
                    <count group_id="O3" value="651"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="14.9" upper_limit="18.8"/>
                    <measurement group_id="O2" value="15.0" lower_limit="13.4" upper_limit="16.8"/>
                    <measurement group_id="O3" value="14.1" lower_limit="12.6" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="665"/>
                    <count group_id="O2" value="660"/>
                    <count group_id="O3" value="650"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="9.2" upper_limit="11.8"/>
                    <measurement group_id="O2" value="11.0" lower_limit="9.6" upper_limit="12.5"/>
                    <measurement group_id="O3" value="11.7" lower_limit="10.3" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="663"/>
                    <count group_id="O2" value="667"/>
                    <count group_id="O3" value="659"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5.9" upper_limit="7.3"/>
                    <measurement group_id="O2" value="6.8" lower_limit="6.1" upper_limit="7.6"/>
                    <measurement group_id="O3" value="7.3" lower_limit="6.5" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="626"/>
                    <count group_id="O3" value="633"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="14.6" upper_limit="19.4"/>
                    <measurement group_id="O2" value="17.4" lower_limit="15.2" upper_limit="20.0"/>
                    <measurement group_id="O3" value="17.0" lower_limit="14.8" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="597"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="22.3" upper_limit="33.1"/>
                    <measurement group_id="O2" value="31.1" lower_limit="25.6" upper_limit="38.0"/>
                    <measurement group_id="O3" value="28.3" lower_limit="23.4" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="647"/>
                    <count group_id="O2" value="641"/>
                    <count group_id="O3" value="641"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="7.2" upper_limit="9.7"/>
                    <measurement group_id="O2" value="7.7" lower_limit="6.6" upper_limit="8.9"/>
                    <measurement group_id="O3" value="7.5" lower_limit="6.5" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR in Serotype-specific IgG Following Vaccination With Separate V114 Lots</title>
        <description>The geometric mean concentration (GMC) of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. The GMFR is the geometric mean of the ratio Day 30/Day 1 IgG concentration. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
        <time_frame>Day 1 (Baseline) and Day 30</time_frame>
        <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR in Serotype-specific IgG Following Vaccination With Separate V114 Lots</title>
          <description>The geometric mean concentration (GMC) of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. The GMFR is the geometric mean of the ratio Day 30/Day 1 IgG concentration. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
          <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="698"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="9.8" upper_limit="12.2"/>
                    <measurement group_id="O2" value="11.2" lower_limit="10.1" upper_limit="12.4"/>
                    <measurement group_id="O3" value="10.3" lower_limit="9.2" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.9" upper_limit="5.9"/>
                    <measurement group_id="O2" value="6.3" lower_limit="5.7" upper_limit="6.9"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.8" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="673"/>
                    <count group_id="O2" value="672"/>
                    <count group_id="O3" value="664"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="7.8" upper_limit="9.5"/>
                    <measurement group_id="O2" value="10.5" lower_limit="9.5" upper_limit="11.6"/>
                    <measurement group_id="O3" value="7.9" lower_limit="7.1" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.1" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.9" upper_limit="6.0"/>
                    <measurement group_id="O3" value="4.7" lower_limit="4.2" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="20.1" upper_limit="25.3"/>
                    <measurement group_id="O2" value="24.1" lower_limit="21.5" upper_limit="27.1"/>
                    <measurement group_id="O3" value="22.9" lower_limit="20.4" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="21.0" upper_limit="26.3"/>
                    <measurement group_id="O2" value="24.1" lower_limit="21.5" upper_limit="27.0"/>
                    <measurement group_id="O3" value="22.1" lower_limit="19.7" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="10.5" upper_limit="13.1"/>
                    <measurement group_id="O2" value="14.8" lower_limit="13.2" upper_limit="16.6"/>
                    <measurement group_id="O3" value="12.0" lower_limit="10.7" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="673"/>
                    <count group_id="O3" value="665"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="8.6" upper_limit="10.5"/>
                    <measurement group_id="O2" value="9.8" lower_limit="8.9" upper_limit="10.9"/>
                    <measurement group_id="O3" value="9.6" lower_limit="8.6" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5.8" upper_limit="7.3"/>
                    <measurement group_id="O2" value="6.8" lower_limit="6.1" upper_limit="7.7"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.7" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="18.3" upper_limit="23.1"/>
                    <measurement group_id="O2" value="17.0" lower_limit="15.1" upper_limit="19.1"/>
                    <measurement group_id="O3" value="15.9" lower_limit="14.2" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="8.2" upper_limit="10.0"/>
                    <measurement group_id="O2" value="10.6" lower_limit="9.6" upper_limit="11.7"/>
                    <measurement group_id="O3" value="9.5" lower_limit="8.6" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="673"/>
                    <count group_id="O3" value="665"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="11.1" upper_limit="13.7"/>
                    <measurement group_id="O2" value="13.8" lower_limit="12.5" upper_limit="15.4"/>
                    <measurement group_id="O3" value="13.1" lower_limit="11.8" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="665"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="12.7" upper_limit="16.1"/>
                    <measurement group_id="O2" value="16.2" lower_limit="14.4" upper_limit="18.1"/>
                    <measurement group_id="O3" value="14.8" lower_limit="13.2" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="11.4" upper_limit="14.4"/>
                    <measurement group_id="O2" value="13.4" lower_limit="11.8" upper_limit="15.1"/>
                    <measurement group_id="O3" value="11.1" lower_limit="9.9" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="673"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="8.3" upper_limit="10.3"/>
                    <measurement group_id="O2" value="9.5" lower_limit="8.6" upper_limit="10.6"/>
                    <measurement group_id="O3" value="7.9" lower_limit="7.1" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥4 Fold Change in Serotype-specific OPA Following Vaccination With Separate V114 Lots</title>
        <description>Sera from participants was used to measure GMT of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, with the MOPA which reads the reciprocal of the highest dilution (1/dil) that gives ≥50% bacterial killing. Percentage of participants with a ≥ 4-fold change from Day 1 (baseline) to Day 30 (Day 30/Day 1) are presented. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
        <time_frame>Day 1 (Baseline) and Day 30</time_frame>
        <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4 Fold Change in Serotype-specific OPA Following Vaccination With Separate V114 Lots</title>
          <description>Sera from participants was used to measure GMT of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, with the MOPA which reads the reciprocal of the highest dilution (1/dil) that gives ≥50% bacterial killing. Percentage of participants with a ≥ 4-fold change from Day 1 (baseline) to Day 30 (Day 30/Day 1) are presented. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
          <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="698"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="667"/>
                    <count group_id="O3" value="661"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" lower_limit="70.9" upper_limit="77.7"/>
                    <measurement group_id="O2" value="76.8" lower_limit="73.4" upper_limit="79.9"/>
                    <measurement group_id="O3" value="77.2" lower_limit="73.8" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="666"/>
                    <count group_id="O2" value="665"/>
                    <count group_id="O3" value="657"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" lower_limit="61.0" upper_limit="68.3"/>
                    <measurement group_id="O2" value="68.9" lower_limit="65.2" upper_limit="72.4"/>
                    <measurement group_id="O3" value="64.8" lower_limit="61.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="670"/>
                    <count group_id="O2" value="663"/>
                    <count group_id="O3" value="658"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.4" lower_limit="76.1" upper_limit="82.4"/>
                    <measurement group_id="O2" value="83.6" lower_limit="80.5" upper_limit="86.3"/>
                    <measurement group_id="O3" value="79.5" lower_limit="76.2" upper_limit="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="675"/>
                    <count group_id="O3" value="665"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="67.7" upper_limit="74.7"/>
                    <measurement group_id="O2" value="76.1" lower_limit="72.7" upper_limit="79.3"/>
                    <measurement group_id="O3" value="69.5" lower_limit="65.8" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="620"/>
                    <count group_id="O2" value="618"/>
                    <count group_id="O3" value="611"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="75.1" upper_limit="81.7"/>
                    <measurement group_id="O2" value="77.8" lower_limit="74.3" upper_limit="81.0"/>
                    <measurement group_id="O3" value="76.9" lower_limit="73.4" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="659"/>
                    <count group_id="O2" value="658"/>
                    <count group_id="O3" value="653"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="80.2" upper_limit="86.1"/>
                    <measurement group_id="O2" value="83.6" lower_limit="80.5" upper_limit="86.3"/>
                    <measurement group_id="O3" value="84.5" lower_limit="81.5" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="648"/>
                    <count group_id="O2" value="638"/>
                    <count group_id="O3" value="646"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" lower_limit="65.7" upper_limit="73.0"/>
                    <measurement group_id="O2" value="71.6" lower_limit="68.0" upper_limit="75.1"/>
                    <measurement group_id="O3" value="70.4" lower_limit="66.7" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="652"/>
                    <count group_id="O2" value="650"/>
                    <count group_id="O3" value="641"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4" lower_limit="49.5" upper_limit="57.3"/>
                    <measurement group_id="O2" value="51.2" lower_limit="47.3" upper_limit="55.1"/>
                    <measurement group_id="O3" value="53.2" lower_limit="49.3" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="671"/>
                    <count group_id="O2" value="667"/>
                    <count group_id="O3" value="662"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="52.9" upper_limit="60.6"/>
                    <measurement group_id="O2" value="57.6" lower_limit="53.7" upper_limit="61.4"/>
                    <measurement group_id="O3" value="52.3" lower_limit="48.4" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="669"/>
                    <count group_id="O2" value="662"/>
                    <count group_id="O3" value="651"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" lower_limit="76.9" upper_limit="83.1"/>
                    <measurement group_id="O2" value="79.0" lower_limit="75.7" upper_limit="82.0"/>
                    <measurement group_id="O3" value="78.3" lower_limit="75.0" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="665"/>
                    <count group_id="O2" value="660"/>
                    <count group_id="O3" value="650"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" lower_limit="64.1" upper_limit="71.4"/>
                    <measurement group_id="O2" value="69.8" lower_limit="66.2" upper_limit="73.3"/>
                    <measurement group_id="O3" value="71.2" lower_limit="67.6" upper_limit="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="663"/>
                    <count group_id="O2" value="667"/>
                    <count group_id="O3" value="659"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="57.0" upper_limit="64.5"/>
                    <measurement group_id="O2" value="61.9" lower_limit="58.1" upper_limit="65.6"/>
                    <measurement group_id="O3" value="63.0" lower_limit="59.2" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="626"/>
                    <count group_id="O3" value="633"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" lower_limit="71.7" upper_limit="78.7"/>
                    <measurement group_id="O2" value="78.3" lower_limit="74.8" upper_limit="81.4"/>
                    <measurement group_id="O3" value="78.2" lower_limit="74.8" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="597"/>
                    <count group_id="O3" value="602"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" lower_limit="67.4" upper_limit="74.7"/>
                    <measurement group_id="O2" value="73.4" lower_limit="69.6" upper_limit="76.9"/>
                    <measurement group_id="O3" value="72.8" lower_limit="69.0" upper_limit="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="647"/>
                    <count group_id="O2" value="641"/>
                    <count group_id="O3" value="641"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" lower_limit="55.6" upper_limit="63.3"/>
                    <measurement group_id="O2" value="58.3" lower_limit="54.4" upper_limit="62.2"/>
                    <measurement group_id="O3" value="56.8" lower_limit="52.8" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥4 Fold Change in Serotype-specific IgG Following Vaccination With Separate V114 Lots</title>
        <description>The geometric mean concentration of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. Percentage of participants with a ≥ 4-fold change from Day 1 (baseline) to Day 30 (Day 30/ Day 1) are presented. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
        <time_frame>Day 1 (Baseline) and Day 30</time_frame>
        <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Lot 1</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>V114 Lot 2</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O3">
            <title>V114 Lot 3</title>
            <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
          </group>
          <group group_id="O4">
            <title>Prevnar13™</title>
            <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥4 Fold Change in Serotype-specific IgG Following Vaccination With Separate V114 Lots</title>
          <description>The geometric mean concentration of IgG serotype-specific antibodies to the 13 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) contained in V114 and Prevnar 13™; and two serotypes (22F and 33F) which are unique to V114, were quantitated from participants' sera by ECL. Percentage of participants with a ≥ 4-fold change from Day 1 (baseline) to Day 30 (Day 30/ Day 1) are presented. Per the statistical analysis plan, the Prevnar 13™ treatment group was not analyzed.</description>
          <population>All randomized participants without deviations from the protocol that may substantially affect the results of the outcome measure. Deviations include randomized but not vaccinated, missing results for serotypes, blood drawn out of time window, prohibited concomitant medication or vaccination.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="698"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="700"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="70.4" upper_limit="77.1"/>
                    <measurement group_id="O2" value="75.2" lower_limit="71.8" upper_limit="78.4"/>
                    <measurement group_id="O3" value="73.0" lower_limit="69.4" upper_limit="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="54.8" upper_limit="62.4"/>
                    <measurement group_id="O2" value="61.9" lower_limit="58.1" upper_limit="65.6"/>
                    <measurement group_id="O3" value="54.7" lower_limit="50.8" upper_limit="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="673"/>
                    <count group_id="O2" value="672"/>
                    <count group_id="O3" value="664"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" lower_limit="65.1" upper_limit="72.3"/>
                    <measurement group_id="O2" value="73.8" lower_limit="70.3" upper_limit="77.1"/>
                    <measurement group_id="O3" value="65.7" lower_limit="61.9" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" lower_limit="41.8" upper_limit="49.5"/>
                    <measurement group_id="O2" value="52.5" lower_limit="48.7" upper_limit="56.3"/>
                    <measurement group_id="O3" value="45.9" lower_limit="42.1" upper_limit="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" lower_limit="83.8" upper_limit="89.0"/>
                    <measurement group_id="O2" value="87.2" lower_limit="84.5" upper_limit="89.7"/>
                    <measurement group_id="O3" value="83.8" lower_limit="80.8" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="84.2" upper_limit="89.4"/>
                    <measurement group_id="O2" value="85.6" lower_limit="82.7" upper_limit="88.2"/>
                    <measurement group_id="O3" value="84.2" lower_limit="81.2" upper_limit="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" lower_limit="71.9" upper_limit="78.5"/>
                    <measurement group_id="O2" value="78.8" lower_limit="75.5" upper_limit="81.8"/>
                    <measurement group_id="O3" value="74.8" lower_limit="71.3" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="673"/>
                    <count group_id="O3" value="665"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="69.1" upper_limit="76.0"/>
                    <measurement group_id="O2" value="73.0" lower_limit="69.4" upper_limit="76.3"/>
                    <measurement group_id="O3" value="71.6" lower_limit="68.0" upper_limit="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" lower_limit="50.6" upper_limit="58.2"/>
                    <measurement group_id="O2" value="57.9" lower_limit="54.0" upper_limit="61.6"/>
                    <measurement group_id="O3" value="48.3" lower_limit="44.5" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="676"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="81.7" upper_limit="87.3"/>
                    <measurement group_id="O2" value="78.6" lower_limit="75.3" upper_limit="81.7"/>
                    <measurement group_id="O3" value="76.7" lower_limit="73.3" upper_limit="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="67.0" upper_limit="74.0"/>
                    <measurement group_id="O2" value="74.2" lower_limit="70.7" upper_limit="77.5"/>
                    <measurement group_id="O3" value="71.0" lower_limit="67.4" upper_limit="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="673"/>
                    <count group_id="O3" value="665"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="74.5" upper_limit="80.9"/>
                    <measurement group_id="O2" value="79.0" lower_limit="75.8" upper_limit="82.1"/>
                    <measurement group_id="O3" value="78.6" lower_limit="75.3" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="665"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" lower_limit="72.7" upper_limit="79.2"/>
                    <measurement group_id="O2" value="80.7" lower_limit="77.5" upper_limit="83.6"/>
                    <measurement group_id="O3" value="76.7" lower_limit="73.3" upper_limit="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="674"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" lower_limit="71.9" upper_limit="78.5"/>
                    <measurement group_id="O2" value="75.4" lower_limit="71.9" upper_limit="78.6"/>
                    <measurement group_id="O3" value="72.1" lower_limit="68.5" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="677"/>
                    <count group_id="O2" value="673"/>
                    <count group_id="O3" value="666"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" lower_limit="65.8" upper_limit="72.9"/>
                    <measurement group_id="O2" value="70.9" lower_limit="67.3" upper_limit="74.3"/>
                    <measurement group_id="O3" value="66.1" lower_limit="62.3" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse events (AEs) were reported from Day 1 through Day 14 following vaccination. Serious AEs (SAEs) were reported from Day 1 following vaccination up to Month 6. All-Cause Mortality were reported from randomization up to Month 6.</time_frame>
      <desc>For SAEs and Non-serious AEs the population analyzed was randomized participants according to the intervention they actually received. One participant randomized to the Prevnar 13™ group incorrectly received V114 Lot 1. For All-Cause Mortality the population analyzed was all randomized participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>V114 Lot 1</title>
          <description>Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="E2">
          <title>V114 Lot 2</title>
          <description>Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="E3">
          <title>V114 Lot 3</title>
          <description>Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)</description>
        </group>
        <group group_id="E4">
          <title>Prevnar 13™</title>
          <description>Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="702"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="701"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="704"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="700"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Due to unknown cause</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="699"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="704"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="699"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="704"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="700"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="548" subjects_at_risk="699"/>
                <counts group_id="E2" subjects_affected="534" subjects_at_risk="704"/>
                <counts group_id="E3" subjects_affected="535" subjects_at_risk="700"/>
                <counts group_id="E4" subjects_affected="151" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="202" subjects_affected="154" subjects_at_risk="699"/>
                <counts group_id="E2" events="182" subjects_affected="147" subjects_at_risk="704"/>
                <counts group_id="E3" events="189" subjects_affected="151" subjects_at_risk="700"/>
                <counts group_id="E4" events="74" subjects_affected="51" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="82" subjects_affected="77" subjects_at_risk="699"/>
                <counts group_id="E2" events="91" subjects_affected="86" subjects_at_risk="704"/>
                <counts group_id="E3" events="91" subjects_affected="89" subjects_at_risk="700"/>
                <counts group_id="E4" events="24" subjects_affected="22" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="518" subjects_affected="464" subjects_at_risk="699"/>
                <counts group_id="E2" events="520" subjects_affected="475" subjects_at_risk="704"/>
                <counts group_id="E3" events="514" subjects_affected="471" subjects_at_risk="700"/>
                <counts group_id="E4" events="134" subjects_affected="122" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="115" subjects_affected="111" subjects_at_risk="699"/>
                <counts group_id="E2" events="117" subjects_affected="115" subjects_at_risk="704"/>
                <counts group_id="E3" events="109" subjects_affected="106" subjects_at_risk="700"/>
                <counts group_id="E4" events="34" subjects_affected="34" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="68" subjects_affected="53" subjects_at_risk="699"/>
                <counts group_id="E2" events="54" subjects_affected="49" subjects_at_risk="704"/>
                <counts group_id="E3" events="75" subjects_affected="59" subjects_at_risk="700"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="226" subjects_affected="196" subjects_at_risk="699"/>
                <counts group_id="E2" events="196" subjects_affected="171" subjects_at_risk="704"/>
                <counts group_id="E3" events="226" subjects_affected="199" subjects_at_risk="700"/>
                <counts group_id="E4" events="54" subjects_affected="50" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="166" subjects_affected="127" subjects_at_risk="699"/>
                <counts group_id="E2" events="170" subjects_affected="140" subjects_at_risk="704"/>
                <counts group_id="E3" events="171" subjects_affected="130" subjects_at_risk="700"/>
                <counts group_id="E4" events="53" subjects_affected="43" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

